SCHOTT and Primoceler join forces to advance the next generation of ultra-miniature, ultra-reliable medical implants

Biocompatible full-glass micro packages offer new possibilities for the next generation of medical implants, such as retinal implants and neuro stimulators, blood pressure sensors, and devices for cardiac rhythm management, including cardiac resynchronization therapy (CRT) and implantable cardioverter defibrillator (ICD) devices.

With this acquisition, SCHOTT will vertically integrate offering Primoceler’s hermetic bonding services alongside its longstanding core competence of hermetic packaging components for a variety of high-reliability applications. The transaction is expected to be completed before the end of 2018, subject to certain customary closing conditions. Upon finalization of the acquisition, the company will conduct its business activities under the new name SCHOTT Primoceler Oy based in Tampere, Finland, as part of SCHOTT’s Electronic Packaging division.

SCHOTT has an established portfolio of vacuum-tight seals made with only inorganic materials (such as glass, ceramics, and metal) that prevent the intrusion of moisture and harmful gases. The portfolio includes hermetically sealed packages and feedthroughs based on glass-to-metal sealing (GTMS) and ceramic-to-metal sealing (CerTMS®) technologies, full ceramic packages, as well as HermeS® glass wafer substrates with hermetically sealed “through glass vias” (TGV), enabling wafer level chip size packaging.